After many quarters, Chennai-based Orchid Pharma turned profitable. The company has posted a consolidated net profit of ₹6.73 crore for the third quarter of the current fiscal against a consolidated net loss of ₹4.67 crore for the same quarter of the previous fiscal. In September 2022 quarter, the company’s net loss stood at ₹3.32 crore.
Consolidated revenue from operations was marginally down to ₹159.76 crore in Q3FY23 against ₹161.37 crore during the corresponding period of the previous fiscal.
Established in 1992, Orchid Pharma is involved in R&D, manufacture, marketing, and export of active pharmaceutical ingredients (APIs) and finished dosage forms (FDF) for segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products. The drug-maker exports to over 40 countries. In April 2020, Gurugram-based Dhanuka Laboratories took over Orchid Pharma under a corporate insolvency resolution plan. After the restructuring process, Orchid Pharma shares were relisted on the bourses on November 3, 2020.
Shares of Orchid Pharma on Friday closed at ₹391.55 apiece on NSE, 2.02 per cent higher than previous day’s close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.